09.30.24 -- When Should You Select Your Supply Partner?

Join the next Outsourced Pharma Live as our panel explores the critical considerations and best practices for selecting and managing CDMOs in the development of novel therapies, including advanced therapy medicinal products like cell and gene therapies. Industry experts will share insights on evaluating CDMO capabilities, ensuring quality and compliance, and fostering effective partnerships to accelerate innovation while mitigating risks.

BioPlan Associates' latest manufacturing survey found signs of a maturing market and strong demand for innovation upstream and downstream.

Our panelists describe how the landscape of today’s CDMOs continues to “shift,” what that means, and how to select and form solid partnerships within the changes.

Reducing risk while maximizing API volume is critical during the fill finish phase of manufacturing. To ensure safety and quality, partner with an experienced fill finish provider.

Investing in employee training and development is not just beneficial for the employees. It also contributes significantly to the organization’s success and competitive advantage.

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. A CDMO can help bring these treatments to patients safely and efficiently.

A partner who is dedicated to providing state-of-the-art services and working collaboratively with clients can support the production of innovative therapies in the biomanufacturing industry.

Discover why bioanalytics are crucial to selecting promising drug candidates during development and to characterizing the pharmacokinetic and pharmacodynamic profile of the drug in early clinical trials.

Learn about the development of a serum-free suspension MDCK cell line that serves as an optimal platform for isolating human influenza viruses from clinical samples and producing vaccines at scale.

Radiofrequency identification (RFID)-based unit-level tracking solutions for prefilled syringes are poised to help pharma manufacturers address key risks and costly bottlenecks related to the fill-finish process.

Discover a chito-oligosaccharide that significantly improves the solubility of antibody-drug conjugates (ADCs) when included in the linker-payload construct.

Uncover a comprehensive framework for conducting robust comparability studies that ensure biosimilars meet stringent standards for safety, efficacy, and quality.

Learn about the process conditions and protocols that were chosen as optimization targets and the resulting improvements to ADC production and purification.

Improve your cell line performance and process optimization using a cloud bioreactor that enable accurate, real-time monitoring of the whole cell culture fluid mass.

Utilizing expert analytical testing services can unlock the potential of biosimilars and bring cost-effective treatments to market faster.

Hilary Eaton, Ph.D. was a self-described AI skeptic, particularly regarding using the tool in drug discovery. Then, a series of professional and deeply personal life events and medical discoveries put her in a position to confront that skepticism head-on. On Business of Biotech, the Chief Business Officer at ProFluent Bio shares her story and makes a pragmatic case for the transformative value of AI to biotech builders. Listen now!

CEO and Founder of INCOG BioPharma Services, Cory Lewis, explains how we are proud to be able to manufacture for the future of medicine.

Learn in-depth about a single-use, automated filtration system designed with a compact form factor for operator convenience and configurable to meet your unique process requirements.

With services to develop and scale up Probiotics, Postbiotics, and Microbial Therapeutics, explore how our capabilities can take your drug product to market safely and efficiently.

Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.

Mycenax’s state-of-the-art biomanufacturing site is PIC/S GMP certified. Our highly qualified and well-trained team routinely manufactures high-quality biopharmaceutical products by mammalian cell culture and microbial fermentation processes.